Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Ähnliche Einträge

• Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
  von: Jabbour, Elias, et al.
  Veröffentlicht: (2008)
• Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
  von: Jabbour, Elias, et al.
  Veröffentlicht: (2010)
• Kinase Domain Point Mutations in Ph+ Acute Lymphoblastic Leukemia (ALL) Emerge Following Therapy with BCR-ABL Kinase Inhibitors
  von: Jones, Dan, et al.
  Veröffentlicht: (2008)
• Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy
  von: Quintás-Cardama, Alfonso, et al.
  Veröffentlicht: (2011)
• Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
  von: Jabbour, Elias, et al.
  Veröffentlicht: (2012)